Is Saccharomyces Boulardii Antibiotic-Associated Diarrhea Meta-Analysis safe?

The current Migaku evidence database contains 2 reusable source documents for Saccharomyces Boulardii Antibiotic-Associated Diarrhea Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts. - Introduction: Antibiotic-associated diarrhea (AAD) is a common complication of antibiotic therapy, while evidence supporting Saccharomyces boulardii for its prevention among hospitalized adults in resource-constrained settings remains limited. [Kovacevic P (2026); evidence level 2] - AAD occurred in 4/51 participants (7.8%) receiving Bularen ® and 35/49 (71.4%) receiving placebo (risk ratio, 0.11; 95% confidence interval, 0.04-0.29; p p p Clostridioides difficile infections were identified. [Kovacevic P (2026); evidence level 2] - Conclusions: Bularen ® substantially reduced AAD incidence in this study population. [Kovacevic P (2026); evidence level 2] - We evaluated the efficacy of Bularen ® in preventing AAD among hospitalized adults receiving systemic antibiotics. [Kovacevic P (2026); evidence level 2] - As a result, it does not reach the colon and is not expected to affect the colonic microbiota. [Hodzhev Vladimir (2025); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.